Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design
First author：刘丽萍
Corresponding author：王拥军,Jiang He
essential_information
2021-03-16
Published articles
Journal：Stroke and Vascular Neurology
Publication type: Protocol
IF(IF): 4.081
PMID: 33727409 Link To Pubmed Full text Download
Background And Purpose
Increased blood pressure (BP) for patients who had an acute ischaemic stroke is associated with poor functional outcome, however the optimal timing of antihypertensive therapy is unknown.We aim to compare early antihypertensive treatment to delayed antihypertensive treatment for reducing the risk of composite major disability and mortality at 3 months in acute ischaemic stroke.
Method
The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) trial is a multicentre, randomised, open- label, blinded-endpoints trial that will be conducted in 100 hospitals in China. The primary outcome is the composite of death and major disability (modified Rankin Scale score ≥3) at 3 months of randomisation.
Conclusion
The CATIS-2 trial will be testing the hypotheses that early BP lowering leads to improved functional outcome without any other harms, and developing clinical guidelines of the BP management for patients who had an acute ischaemic stroke.
Main results
Antihypertensive treatment will be received immediately after randomisation in the early treatment group, aimed at average systolic BP by 10%–20% reduction within the first 24 hours, and achieving an average BP level of <140/90 mmHg within 5 days. Patients in the delayed treatment group will discontinue any antihypertension medications for the first 7 days of randomisation, and will receive antihypertensive therapy achieving a BP goal of <140/90 mmHg after 7 days.